Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3498264 + Sotorasib in Advanced KRASG12C-mutated Solid Tumors
NCT06659341Phase 1Recruiting
- Sponsor
- Bayer
- Start
- Nov 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of BAY3498264 in solid tumor (3 arms), sponsored by Bayer. Primary endpoints: Treatment-Emergent Adverse Events, Maximum Tolerated Dose or Maximum Administered Dose and 3 more. Started Nov 2024; status: recruiting.
02
Drugs
BAY3498264
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06659341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06659341.